Effect of Bumetanide on brain function in autism spectrum disorder

Evaluating the effect of Bumetanide on brain functions in facial emotion recognition and attention to eyes, in children and adolescence with autism spectrum disorder

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180901040915N1

Enrollment

Registered

2019-07-06

Start date

2017-09-23

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder. Autistic disorder

Interventions

Intervention group: Receiving 1 mg (0.5 m.g in the morning, 0.5 m.g in the evening) Bumetanide (Purchased from Niche Generics Limited Ireland) twice a day for three months.

Eligibility

Sex/Gender

All

Age

7 Years to 16 Years

Inclusion criteria

Inclusion criteria: Diagnosed as a autism spectrum disorder, level 1 (needing support) according to DSM-V IQ above 70

Exclusion criteria

Exclusion criteria: Karyotype abnormalities or neurological records including epilepsy and febrile seizures A history of allergy to sulfonamides liver or kidney dysfunction, heart disease

Design outcomes

Primary

Measure	Time frame
Evaluation of the latency and amplitude of brain signals faced with emotional faces. Timepoint: Before the intervention and one week after the intervention. Method of measurement: Brain Event Related Potentials Recording.;Attention to eyes. Timepoint: Before the intervention and one week after the intervention. Method of measurement: Eye Track Recording.	—

Secondary

Measure	Time frame
Severity of the symptoms. Timepoint: One week before the intervention, sixth week of the intervention, and one week after the intervention. Method of measurement: Interview with the parents and completing the "Childhood Autism Rating Scale" questionnaire.;Evaluation of the communication and social relationships. Timepoint: One week before the intervention, sixth week of the intervention, and one week after the intervention. Method of measurement: "Social Responsiveness Scale" questionnaire completion.	—

Measure

Time frame

Severity of the symptoms. Timepoint: One week before the intervention, sixth week of the intervention, and one week after the intervention. Method of measurement: Interview with the parents and completing the "Childhood Autism Rating Scale" questionnaire.;Evaluation of the communication and social relationships. Timepoint: One week before the intervention, sixth week of the intervention, and one week after the intervention. Method of measurement: "Social Responsiveness Scale" questionnaire completion.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Tehranidoost

Institute for Cognitive Science Studies

tehranid@tums.ac.ir+98 21 7629 1130

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026